Posted by Michael Wonder on 21 Feb 2023
ICER publishes final evidence report on treatments for multiple sclerosis
21 February 2023 - Independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit for ublituximab when compared to other monoclonal antibodies.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of a range of treatments for multiple sclerosis.
